JacquelineVukyMD

Oncology • Portland, OR

Genitourinary Oncology

Associate Professor, Division Hematology-Oncology, Oregon Health and Science University School of Medicine

Join to view full profile

Dr. Vuky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vuky's full profile

Already have an account?

Office
3485 S. Bond Avenue
OCP14P
Portland, OR 97239
Phone+1 503-494-1091

Fax+1 503-494-6197

Summary

Dr. Jacqueline Vuky, based in Portland, OR, is an accomplished Oncologist specializing in Genitourinary Oncology. She is an Associate Professor at Oregon Health and Science University, where she has been serving since 2011. Dr. Vuky completed her fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center and her residency in Internal Medicine at New York Presbyterian- Cornell Medical Center. Aside from her extensive experience in various fields such as breast cancer, prostate, bladder, kidney and testis cancer, she has participated in several clinical trials and boasts considerable contributions in the form of publications in renowned journals. She has been recognized with the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2012-2013.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1995 - 1998
Oregon Health and Science University School of MedicineClass of 1995

Certifications & Licensure

MT State Medical License 2022 - 2026
OH State Medical License 2024 - 2026
OR State Medical License 2011 - 2025
WA State Medical License 2001 - 2012
NY State Medical License 1996 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer Start of enrollment: 2003 May 01
Completed
Phase 2
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer Start of enrollment: 2006 Apr 01
Unknown status
Phase 2
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
Completed
Phase 2
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Start of enrollment: 2010 Dec 01
Completed
Phase 3
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Start of enrollment: 2011 Jan 01
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer Start of enrollment: 2012 May 16
Completed
Not Applicable
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Start of enrollment: 2018 Oct 31
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Start of enrollment: 2019 Dec 10
Active, not recruiting
Phase 1
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analys...
Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, Nobuaki Matsubara, Sang Joon Shin
Cancer. 2024-10-28
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Hans Gelderblom, Albiruni A Razak, Matthew H Taylor, Todd M Bauer, Breelyn Wilky
Clinical Cancer Research. 2024-09-13
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutation...
Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves
Journal for Immunotherapy of Cancer. 2024-08-06

Lectures

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial canc...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018